[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Giessen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":424},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,41,71,100,127,155,175,198,218,240,258,284,312,339,358,381,406],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100631809","early-phase-1-visualization-of-the-effects-of-guideline-directed-medical-therapy-gdmt-on-improving-adherence-and-quality-of-life-in-heart-failure-with-reduced-ejection-fraction-hfref-100631809",false,"NCT07505511","Visualization of the Effects of Guideline-directed Medical Therapy (GDMT) on Improving Adherence and Quality of Life in Heart Failure With Reduced Ejection Fraction (HFrEF)","VISUALIZE-PRO","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of heart failure with reduced ejection fraction (HFrEF) (left ventricular ejection fraction ≤40%)\n* Indication for guideline-directed medical therapy (GDMT) for heart failure\n* Stable clinical condition at the time of enrollment\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Acute decompensated heart failure requiring immediate hospitalization\n* Severe cognitive impairment or inability to understand study-related information\n* Life expectancy \\\u003C6 months due to non-cardiac comorbidities\n* Participation in another interventional clinical trial that may interfere with this study\n* Contraindications to prescribed heart failure medications\n* Any condition that, in the investigator's judgment, precludes safe participation in the study","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","Heart failure with reduced ejection fraction (HFrEF) remains a major public health challenge with substantial morbidity and mortality despite the availability of effective guideline-directed medical therapy (GDMT). Although four major drug classes have been shown to significantly improve survival and reduce hospitalizations, real-world implementation remains suboptimal. In addition to underutilization by healthcare providers, poor medication adherence among patients-reported to range between 29% and 63%-represents a critical barrier to achieving optimal therapeutic benefit.\n\nThe Visualize-Pro study is a prospective, exploratory pilot study designed to evaluate a simple, patient-centered intervention aimed at improving medication adherence in patients with HFrEF. The intervention consists of patient-friendly graphical visualizations illustrating the survival benefits and risk reduction associated with optimal heart failure therapy. These materials are designed to enhance patient understanding, motivation, and engagement with prescribed treatments.\n\nTo objectively assess medication adherence, this study incorporates therapeutic drug monitoring (TDM) as a gold standard method, in addition to established patient-reported outcome measures such as quality of life and adherence questionnaires. Blood samples will be collected at predefined study visits, and drug levels (or their metabolites) will be analyzed in collaboration with a specialized laboratory to quantify adherence.\n\nParticipants will be followed over a predefined study period with serial assessments at scheduled visits.\n\nThe primary objective is to evaluate the feasibility and preliminary effectiveness of the intervention in improving medication adherence. Secondary objectives include assessing changes in patient-reported outcomes and exploring associations between adherence and clinical parameters.\n\nAs a pilot study, the results are intended to inform the design of a future large-scale, multicenter trial. Ultimately, this approach aims to provide a scalable and low-threshold strategy to improve adherence to life-saving therapies in heart failure, thereby contributing to reduced morbidity and mortality in this high-risk population.",[26,27,28],"Adherence, Medication","Adherence, Treatment","Heart Failure","NOT_YET_RECRUITING","2026-03-29",{"date":32,"type":33},"2026-04-01","ACTUAL",{"date":35,"type":20},"2026-03-01",{"date":37,"type":20},"2028-03-01",{"name":39,"class":40},"University of Giessen","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":50,"conditions":51,"keywords":57,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100630499","quality-improvement-project-to-reduce-preoperative-fasting-times-before-elective-procedures-100630499","NCT07488468","Quality Improvement Project to Reduce Preoperative Fasting Times Before Elective Procedures","Inclusion Criteria:\n\n* All patients elective surgery or intervention requiring with anesthesiology care general anesthesia, regional anesthesia, sedation, or anesthesiology stand-by\n\nExclusion Criteria:\n\n* Already sedated, intubated, and mechanically ventilated patients",{"count":48,"type":20},1000,"OBSERVATIONAL","This single-center quality improvement project evaluates preoperative fasting times before elective procedures requiring anesthesiology care. The project aims to reduce prolonged fasting for clear fluids by implementing a local standard operating procedure (SOP) allowing patients to drink clear liquids until being called to the operating room (\"drink until called\"), supported by staff education and fasting instruction cards. Fasting times and selected perioperative outcomes will be assessed before and after implementation.",[52,53,54,55,56],"Preoperative Fasting","Perioperative Patient Comfort \u002F Quality of Care","Postoperative Nausea and Vomiting (PONV)","Postoperative Pulmonary Complications","Delirium",[58,59,60],"Preoperative fasting","clear liquids","quality improvement","RECRUITING","2026-03-17",{"date":64,"type":33},"2026-03-23",{"date":66,"type":33},"2026-01-30",{"date":68,"type":20},"2026-07-30",{"name":39,"class":40},1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":70},"100547327","topical-application-of-prf-before-radiation-therapy-100547327","NCT06406530","Topical Application of PRF Before Radiation Therapy","Topical Application of PRF in Tooth Extraction Sockets Before Radiation Therapy for Head and Neck Cancer","PRF","Inclusion Criteria:\n\n* Head and neck cancer with planed radiation therapy\n* Bilateral tooth extraction\n* Similar tooth size\n* Atraumatic tooth extractions without flap surgery\n* Patients age above 18y of age\n\nExclusion Criteria:\n\n* Prior radiation therapy in the head and neck area\n* Prior and current therapy with bisphosphonates or equivalent modern biologics\n* Patients during pregnancy or breastfeeding","99 Years",{"count":81,"type":20},34,[83],"NA","The primary goal of this study is to observe whether PRP promotes the wound healing before a radiation therapy or not, compared to the natural healing of a tooth extraction socket.\n\nSecondary aim is to monitore the effect on the pain perception.",[77],[77,87,88,89,90,91],"wound healing","dentistry","oral surgery","radiation therapy","cancer","2025-04-08",{"date":94,"type":33},"2025-04-11",{"date":96,"type":33},"2023-12-01",{"date":98,"type":20},"2025-09-01",{"name":39,"class":40},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":108,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":70},"100464593","pvri-godeep-global-deep-phenotyping-meta-registry-for-pulmonary-hypertension-100464593","NCT05329714","PVRI GoDeep Global Deep Phenotyping Meta-Registry for Pulmonary Hypertension","PVRI Global Deep Phenotyping Meta-Registry for Pulmonary Hypertension","PVRI GoDeep","Inclusion Criteria:\n\n* Clinical Diagnosis of Pulmonary Hypertension\n\nExclusion Criteria:\n\n* none",true,{"count":110,"type":20},40000,"PVRI-GoDeep is a PH Meta-Registry, run under the umbrella of the Pulmonary Vascular Research Institute (PVRI). It merges anonymized PH patient related data from various local registries around the world run under the responsibility of PVRI members. It will be operated under the auspices of the University of Giessen\u002FGiessen PH center. Combining deep phenotyping with worldwide outreach, PVRI-GoDeep aims to offer insights into specific geographical and ethnical profiles of PH, to deepen the epidemiological, clinical and molecular understanding of this disease and to promote strategies for improved individualized treatment of PH patients.",[113,114],"Pulmonary Hypertension","Global Health",[113,116,117,114,118],"Data Integration","Standardization","Quality Indicators","2025-04-01",{"date":121,"type":33},"2025-04-04",{"date":123,"type":33},"2020-01-30",{"date":125,"type":20},"2055-01-30",{"name":39,"class":40},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":139,"conditions":140,"keywords":144,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":70},"100538505","non-invasive-measurement-of-the-hypotension-prediction-index-for-the-reduction-of-intraoperative-hypotension-100538505","NCT06291714","Non-invasive Measurement of the Hypotension Prediction Index for the Reduction of Intraoperative Hypotension","Prospective Interventional Study Investigating a Goal-directed Therapy Based on Non-invasive Measurement of the Hypotension Prediction Index for the Reduction of Hypotension in Patients Undergoing Major Orthopedic and Trauma Surgery","Clearsight","Inclusion Criteria:\n\n* Patients undergoing major trauma or orthopedic surgery in supine position, which is defined as:\n\n  * Reconstructive Surgery of the pelvis (e.g., stabilization of fractures)\n  * Total hip arthroplasty\n  * Surgery of the proximal femur (e.g., stabilization of fractures)\n  * Total knee arthroplasty\n  * Surgery of the spine\n\n    * Performance of general anesthesia with planned duration of \\>90min\n    * Age ≥ 45 years\n\nExclusion Criteria:\n\n\\- Predefined exclusion criteria are:\n\n* Planned invasive blood pressure monitoring\n* Participation in another interventional study\n* Pregnancy and nursing mothers\n* Surgery without controlled mechanical ventilation\n* ASA I or IV\n* Arterial Fibrillation\n* Allergy against gelantine","45 Years",{"count":137,"type":20},150,[83],"In order to reduce the incidence of IOH, various goal-directed therapy (GDT) protocols have already been introduced with success regarding the reduction of postoperative AKI and MINS. However, these studies used an invasive hemodynamic monitoring which offered a continuous surveillance of the blood pressure. In contrast, standard non-invasive blood pressure monitoring results in a blind gap between two measurements (mostly three or five minutes). In order to address this limitation, different continuous non-invasive blood pressure monitoring devices have been introduced. The next evolutional step of non-invasive cardiac output monitoring was to prevent IOH before their onset by using the Hypotension Prediction Index (HPI). Based on the Edward ́s monitoring platform, HPI is a monitoring tool which aims to predict IOH (defined as MAP\\\u003C65 mmHg for at least one minute) up to 15 min before its onset. The underlying machine learning based algorithm uses analyses features from the pressure waveform and was first calculated from a large retrospective data set of surgical patients and subsequently validated in a prospective cohort. In this study HPI showed a sensitivity of 88% and specificity of 87% for predicting IOH 15 min before its onset. Since then, own and studies of other working groups confirmed the effective prevention of IOH by the use of HPI-based GDT. Until today the arterial waveform analysis was dependent on invasive arterial measurement but since Edwards Lifesciences already promoted the start of the HPI on the ClearSight platform a non-invasive measurement will soon be possible.\n\nFurther, until now it has not yet been proven that the perioperative use of a continuous non-invasive blood pressure monitoring has a beneficial effect on the patient´s outcome.\n\nStudy objectives The aim of the study is to investigate whether a hemodynamic protocol based on continuous non-invasive cardiac output monitoring (ClearSight system) compared to standard care can reduce the incidence of IOH, postoperative AKI, and MINS in patients undergoing major trauma and orthopedic surgery.",[141,142,143],"Intraoperative Hypotension","Acute Kidney Injury","Myocardial Injury After Non-cardiac Surgery",[141,145,146],"Hypotension Prediction Index","Clearsight system","2025-03-31",{"date":149,"type":33},"2025-04-03",{"date":151,"type":33},"2024-08-01",{"date":153,"type":20},"2026-03-31",{"name":39,"class":40},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":164,"studyType":49,"phases":4,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":70},"100398376","giessen-pulmonary-hypertension-in-lung-cancer-registry-100398376","NCT04467333","Giessen Pulmonary Hypertension in Lung Cancer Registry","PHLHR","Inclusion Criteria:\n\n* Patient with lung cancer at the University of Giessen lung Cancer Center.\n\nExclusion Criteria:\n\n\\-",{"count":163,"type":20},500,"3 Weeks","The aim of this study is to investigate the frequency and implications of pulmonary hypertension in lung cancer patients. To do so, data will be collected from all lung cancer patients at the university hospital Giessen. All data will be analyzed for possible hints of pulmonary hypertension as a comorbidity in lung cancer patients. All information will be generated from the regular guidelines based course of treatment and there will be no interventions. This study will serve as a prospective register for all lung cancer patients treated at the university hospital Giessen.",[167],"Pulmonary Hypertension Due to Lung Diseases and Hypoxia","2025-03-26",{"date":119,"type":33},{"date":171,"type":33},"2020-06-29",{"date":173,"type":20},"2040-01-29",{"name":39,"class":40},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":108,"sex":16,"minAge":182,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":197},"100461311","multidimensional-assessment-of-infant-parent-and-staff-outcomes-during-a-family-centered-care-enhancement-project-100461311","NCT05286983","Multidimensional Assessment of Infant, Parent and Staff Outcomes During a Family Centered Care Enhancement Project","Multidimensional Assessment of Infant, Parent and Staff Outcomes During a Family Centered Care Enhancement Project in a Tertiary Neonatal Intensive Care","Inclusion Criteria:\n\n* ≤32+0 weeks of gestational age (GA) and\u002For birthweight ≤1500g\n* biparental (or guardian) written informed consent\n\nExclusion Criteria:\n\n* severe congenital anomalies (e.g. cyanotic heart disease, severe lung hypoplasia, congenital diaphragmatic hernia)\n* decision not to provide full life support\n* decision for palliative care before study entry\n* parents with severe psychiatric disease","1 Minute","14 Days",{"count":185,"type":20},495,"This prospective single centre longitudinal cohort study enrols preterm infants ≤32+0 weeks of gestation and\u002For birthweight ≤1500g and their parents. Following a baseline period additional Family Centred Care elements are introduced as potentially better practices, these elements focus on four areas: the NICU (Neonatal Intensive Care Unit) environment, staff training, parental education and psychosocial support to the families. The effect of the implementation of additional Family Centred Care elements on infant, parent and staff outcomes are assessed. The parallel data collection enables to study the interrelation between these three important areas of research.",[188],"Family Centered Care","2025-03-25",{"date":191,"type":33},"2025-03-30",{"date":193,"type":33},"2020-10-01",{"date":195,"type":20},"2026-07-01",{"name":39,"class":40},2,{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":212,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":70},"100396491","sequelae-of-sars-cov-2-infections-100396491","NCT04442789","Sequelae of Sars-CoV-2 Infections","Long-term Sequelae of Severe Sars-CoV-2 Infections","Inclusion Criteria:\n\n* hospitalization due to Sars-CoV-2 infection\n\nExclusion Criteria:\n\n* under 18 years of age",{"count":206,"type":20},120,"By the end of 2019 a new coronavirus, named SARS-CoV-2, was discovered in patients with pneumonia in Wuhan, China. In the following weeks and months the virus spread globally, having a tremendous impact on global health and economy. To date, no vaccine or therapy is available. Severe courses of the infection not only affect the lungs, but also other organs like the heart, kidney, or liver. The lack of preexisting immunity might at least partially explain the affection of extra pulmonary organs not yet seen in infections due to other respiratory viruses. In this observational investigation the study group will follow up on patients that have been hospitalized due to a SARS-CoV-2 infection, and monitor sequelae in various organs, with an emphasis on the pulmo-cardiovascular system. Our that in some patients, organ damage will persist and require long-term medical care.",[209,210,211],"Lung Diseases","Cardiac Disease","Inflammatory Reaction",{"date":191,"type":33},{"date":214,"type":33},"2020-05-20",{"date":216,"type":20},"2025-12-31",{"name":39,"class":40},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":226,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":21,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":70},"100545401","perioperative-interdisciplinary-intersectoral-process-optimization-in-heart-failure-100545401","NCT06381427","Perioperative Interdisciplinary, Intersectoral Process Optimization in Heart Failure","Perioperative Interdisciplinary, Intersectoral Process Optimization in Heart Failure: A Multicenter, Prospective-randomized Intervention Study","PeriOP-CARE HF","Inclusion Criteria:\n\n* Age ≥ 65 years\n* Elective non-cardiac surgical operation with intermediate or high operative risk under general anesthesia or combined anesthesia (general and regional anesthesia) as per Figure 1\n* ASA (American Society of Anesthesiologists) grade ≥ II\n* Qualification for randomization: NT-proBNP ≥ 450pg\u002Fml during routine preoperative evaluation and anesthesia consultation.\n\nExclusion Criteria:\n\n* Age \\\u003C 65 years\n* Cardiac surgery and cardiology interventional procedures\n* Transplantation surgery (e.g., kidney, liver, lung transplantation)\n* Kidney surgery (e.g., nephrectomy, partial nephrectomy)\n* Procedures involving cardiopulmonary bypass\n* Emergency surgery\n* Surgery under general anesthesia within the last 30 days\n* Primary use of local or regional anesthesia\n* Chronic kidney insufficiency with eGFR \\\u003C 15 ml\u002Fmin or dialysis-dependent kidney insufficiency\n* Surgical time \\\u003C 30 minutes\n* Participation in another interventional study\n* Lack of consent\n* Limited language proficiency\n* Patient's limited or absent capacity to provide consent, as well as patients under legal guardianship","65 Years",{"count":228,"type":20},1057,[83],"Chronic heart failure affects up to three million people in Germany, with prevalence increasing with age. It is a leading cause of cardiovascular disease-related deaths. Patients with heart failure undergoing non-cardiac surgery face higher risks of complications and death compared to those with coronary artery disease. Despite guidelines recommending comprehensive preoperative evaluation, there is no systematic risk assessment structure in place, leading to inadequate perioperative care. This study aims to evaluate a multidisciplinary approach for high-risk patients aged 65 and above, regardless of prior heart failure diagnosis, to mitigate postoperative complications. The investigators measure the NTpro BNP before surgery and include patients with NTproBNP\\> 450 in this study and randomize them either to the standard care group or the intervention group.The hypothesis is that standardized risk screening and multidimensional care (Intervention group) can reduce complications in these patients undergoing non-cardiac surgery.",[28],"2025-02-26",{"date":234,"type":33},"2025-03-03",{"date":236,"type":33},"2024-09-01",{"date":238,"type":20},"2027-03-01",{"name":39,"class":40},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":246,"targetDuration":248,"studyType":49,"phases":4,"briefSummary":244,"conditions":249,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":70},"100373637","giessen-pulmonary-hypertension-registry-and-biobank-100373637","NCT04145024","Giessen Pulmonary Hypertension Registry and Biobank","Inclusion Criteria:\n\n* Right heart catheterization for PH diagnosis in Giessen\n\nExclusion Criteria:\n\n* informed consent missing",{"count":247,"type":20},10000,"20 Years",[113],"2024-12-10",{"date":252,"type":33},"2024-12-11",{"date":254,"type":33},"1993-07",{"date":256,"type":20},"2036-01-15",{"name":39,"class":40},{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":266,"targetDuration":17,"studyType":49,"phases":4,"briefSummary":268,"conditions":269,"keywords":271,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":70},"100562714","cedata-gpge---a-patient-registry-for-children-and-adolescents-with-inflammatory-bowel-disease-100562714","NCT06606756","CEDATA GPGE - a Patient Registry for Children and Adolescents With Inflammatory Bowel Disease","CEDATA GPGE Patient Registry for Children and Adolescents With IBD","CEDATA GPGE","Inclusion Criteria:\n\n* Inflammatory Bowel Disease\n\nExclusion Criteria:\n\n* none",{"count":267,"type":20},6300,"CEDATA GPGE collects clinical data of children and adolescents with IBD from paediatric gastroenterology centers in german-speaking countries.\n\nData is obtained from participating centers in pseudonymized way via an online platform at the beginning and during followup of the disease. The leading working group of the paediatric gastroenterology society GPGE e.V. includes 15 experts in the field who meet twice yearly and coordinate research and quality improvement initiatives.",[270],"Inflammatory Bowel Disease (IBD)",[272,273,274,60,275],"paediatric","crohns disease","ulcerative colitis","patient registry","2024-09-18",{"date":278,"type":33},"2024-09-23",{"date":280,"type":33},"2004-09-01",{"date":282,"type":20},"2034-12-01",{"name":39,"class":40},{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":290,"enrollmentInfo":291,"targetDuration":4,"studyType":21,"phases":293,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":311},"100219266","phase-2-therapy-optimisation-for-the-treatment-of-hairy-cell-leukemia-100219266","NCT02131753","Therapy Optimisation for the Treatment of Hairy Cell Leukemia","Inclusion Criteria:\n\n* Patients with histologically verified hairy cell leukemia\n* Presence of hairy cells in the bone marrow and peripheral blood detected by positive TRAP staining and \u002F or co expression if cell surface antigens cluster of differentiation (CD) 19\u002FCD25 or CD19\u002FCD103 (b-ly7)\n* No previous cytostatic treatment (splenectomy or interferon treatment are allowed)\n* Need for treatment\n* Age at least 18 years old\n* General state of health according to WHO 0-2\n* Current histology, not older than 6 months\n* Written consent by patient\n\nExclusion Criteria:\n\n* Patients not fulfilling inclusion criteria above\n* Hairy cell leukemia variants (HCL-V): presence of lymphoid cells in bone marrow and \u002F or peripheral blood, which have an intermediate morphology between hairy cells and prolymphocytes (negative TRAP staining and co- expression of CD19\u002FCD103 without CD25\n* Pretreatment with purine analogues or other chemotherapeutics\n* Concomitant corticosteroid therapy\n* Severe dysfunction of the heart (NYHA III or IV), the lung (WHO-Grade III or IV), the liver, except due to lymphoma (bilirubin \\> 2 mg\u002Fdl, alkaline phosphatase, glutamate-oxalacetate transaminase and glutamate-pyruvate transaminase \\> 2 x upper limit of normal), the kidneys (creatinin \\> 2 mg\u002Fdl or creatinine clearance \\\u003C 50 ml\u002Fmin), central nervous system diseases including psychoses.\n* Proven HIV infection\n* Active Hepatitis\n* Other florid infections\n* Anamnesis \u002F diagnosis of other malignant disease (other than non-melanoma associated skin tumours or stage 0 in situ carcinoma of the cervix)\n* Pregnant or lactating women","90 Years",{"count":292,"type":20},210,[294,295],"PHASE2","PHASE3","The trial will test the effectiveness and toxicity of subcutaneous treatment with one cycle of cladribine in patients with hairy cell leukemia requiring treatment.\n\nThey have to be untreated so far or may be pretreated with alpha-interferon.",[298],"Hairy Cell Leukemia",[300,301,302],"hairy cell leukemia","untreated","cladribine subcutaneous","2024-08-20",{"date":305,"type":33},"2024-08-22",{"date":307,"type":4},"2004-05",{"date":309,"type":20},"2027-12",{"name":39,"class":40},76,{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":319,"enrollmentInfo":320,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":322,"conditions":323,"keywords":326,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":70},"100554338","bjh-sds-validation-of-the-german-translation-100554338","NCT06497790","BJH-SDS Validation of the German Translation","German Translation and Validation of the Barnes-Jewish-Hospital Stroke Dysphagia Screen (BJH-SDS)","Inclusion Criteria:\n\n* All stroke patients in the neurology department of the Lahn-Dill Clinic in Wetzlar and the stroke unit of the Bürgerhospital in Friedberg and the neurologic ICU of the University Hospital in Giessen are to be screened with the BJH-SDS-G after appropriate information has been provided.\n\nExclusion Criteria:\n\n* Exclusion criteria are a lack of informed consent, contraindications to an FEES examination, a history of stroke, pre-existing dysphagia or a disease that may be associated with dysphagia (e.g. ENT tumors, Parkinson's disease, neuromuscular diseases).","100 Years",{"count":321,"type":20},570,"The first object of the study is the validation of a translation of the Barnes-Jewish Hospital Stroke Dysphagia Screen with determination of sensitivity, specificity, interrater reliability (especially between different professional groups) and criterion validity.\n\nIf the German translation proves to be suitable, it will also be validated on general neurological patients, i.e. patients on a neurological ward without a stroke.",[324,325],"Dysphagia","Stroke, Acute",[327,324,328,329,330],"Stroke","Swallowing disorders","FEES","Swallow screening","2024-07-04",{"date":333,"type":33},"2024-07-12",{"date":335,"type":33},"2024-04-15",{"date":337,"type":20},"2026-05-01",{"name":39,"class":40},{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":108,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":21,"phases":347,"briefSummary":348,"conditions":349,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":70},"100428990","prevalence-of-gag-reflex-in-healthy-persons-and-across-different-patient-groups-and-its-relevance-in-dysphagia-screening-100428990","NCT04866251","Prevalence of Gag Reflex in Healthy Persons and Across Different Patient Groups and Its Relevance in Dysphagia Screening","Inclusion Criteria:\n\n* informed consent\n\nExclusion Criteria:\n\n1. Healthy participants:\n\n   Neurological diseases Pre-diagnosed dysphagia Percutaneous endoscopic gastrostomy (PEG) tube Head and neck tumours Chemo- and\u002For radiotherapy in the head and neck area Reflux disease Chronic obstructive pulmonary disease (COPD) Previous surgeries on the cervical spine or thyroid gland Vocal cord paresis\n2. Geriatric patients Neurologic diseases\n3. Stroke patients Head and neck tumours Chemo- and\u002For radiotherapy in the head and neck area Reflux disease COPD Previous surgeries on the cervical spine or thyroid gland Vocal cord paresis\n4. Neurologic patients without stroke Head and neck tumours (except of intracranial tumors= Chemo- and\u002For radiotherapy in the head and neck area Reflux disease COPD Previous surgeries on the cervical spine or thyroid gland Vocal cord paresis",{"count":346,"type":20},700,[83],"The aim of this study is to assess the prevalence of gag reflex in healthy young and healthy older subjects as well as in acute stroke patients, in patients with Parkinsons´s Disease, Myasthenia gravis, Multiple Sclerosis and in geriatric patients.",[350],"Neurological Diseases or Conditions",{"date":352,"type":33},"2024-07-08",{"date":354,"type":33},"2016-08-10",{"date":356,"type":20},"2024-07-01",{"name":39,"class":40},{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":366,"targetDuration":368,"studyType":49,"phases":4,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":70},"100531108","dysphagia-after-transesophageal-echocardiography-in-acute-stroke---follow-up-trial-100531108","NCT06195501","Dysphagia After Transesophageal Echocardiography in Acute Stroke - Follow Up Trial","Transoesophageal Echocardiography - Dysphagia Risk in Acute Stroke- TEDRAS 2 - Follow Up","TEDRAS2","Inclusion Criteria:\n\n* Acute cerebral infarction detected by cMRI or cCT\n* Indication for TEE\n* Neurological deficits\n* Written informed consent\n\nExclusion Criteria:\n\n* Cerebral hemorrhage\n* Contraindications to FEES (lack of alertness as well as lack of compliance)",{"count":367,"type":20},40,"2 Years","The aim of the prospective observational TEDRAS - Follow-up Trial is to investigate the limitations of the initial TEDRAS - Trial in patients with acute Dysphagia is a common consequence from ischemic stroke and it correlates with an increased risk of pulmonary complications such as aspiration pneumonia and an increased mortality risk.\n\nTEDRAS-Trial (Transesophageal Echocardiography: Dysphagia Risk in the Acute Phase After Stroke; ClinTrial.gov identifier NCT04302883) was the first randomized and controlled trial to address the question of the extent to which TEE increases dysphagia risk in acute stroke patients. The results of the study confirmed the hypothesis that dysphagia severity worsens after TEE in the intervention group.\n\nThe aim of the prospective observational TEDRAS - Follow-up Trial is to investigate the limitations of the initial TEDRAS - Trial in patients with acute ischemic stroke.",[371,372],"Ischemic Stroke, Acute","Dysphagia Following Cerebrovascular Accident","2024-06-05",{"date":375,"type":33},"2024-06-06",{"date":377,"type":33},"2023-05-01",{"date":379,"type":20},"2025-08-31",{"name":39,"class":40},{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":389,"targetDuration":391,"studyType":49,"phases":4,"briefSummary":392,"conditions":393,"keywords":396,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":402,"completionDateStruct":403,"leadSponsor":405,"locationsCount":70},"100461992","giessen-stroke-registry-100461992","NCT05295862","Giessen Stroke Registry","Giessen Acute Stroke Registry","GIST","Inclusion Criteria:\n\n* Age above 18\n* Patient admitted for acute stroke (Stroke Unit or Intensive Care Unit)\n* Informed Consent\n\nExclusion Criteria:\n\n* Inclusion criteria not met",{"count":390,"type":20},2000,"12 Months","The aim of the planned study project is to assess the current situation regarding the treatment of patients with stroke. Specifically, various treatment strategies are to be associated and correlated with clinical endpoints, mortality or functional outcome in order to generate arguments for or against individual aspects of therapy. The focus will be on unresolved treatment approaches in acute therapy (e.g. periprocedural management, such as blood pressure, blood glucose, temperature, or airway management, during recanalizing therapies) as well as in secondary prevention on the stroke unit or intensive care unit, such as starting point, mode, and dosage of antithrombotic therapies.",[325,394,395],"Comorbidities and Coexisting Conditions","Critical Care",[397,398,399],"Acute Stroke","Comorbidities","Clinical Management","2023-11-30",{"date":96,"type":33},{"date":400,"type":33},{"date":404,"type":20},"2027-12-31",{"name":39,"class":40},{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":108,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":418,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":70},"100304267","changes-in-sensitivity-taste-and-smell-in-stroke-patients-100304267","NCT03240965","Changes in Sensitivity, Taste and Smell in Stroke Patients","Changes in Sensitivity of Swallowing-relevant Structures, Taste and Smell in Stroke Patients","5S","Inclusion Criteria:\n\nVolunteers:\n\n* informed consent\n\nStroke patients:\n\n* informed consent\n* new supratentorial stroke (\\\u003C72 hours old) confirmed by CT (computed tomography) or MRI (magnetic resonance imaging)\n\nExclusion Criteria:\n\n* pre-existing stroke oder dysphagia\n* extensive white matter lesions in CT- or MRI-scan\n* allergies to odorous substances or flavoring\n* contraindications for FEES (flexible endoscopic evaluation of swallowing), CT or MRI (stroke patients only)",{"count":415,"type":20},200,"This study evaluates changes in swallowing using endoscopic swallowing studies and measuring of pharyngeal sensitivity, taste and smell in stroke patients. Younger (\\\u003C60 years) and older (\\>60 years) volunteers will serve as control.",[324,327],{"date":96,"type":33},{"date":420,"type":33},"2017-10-01",{"date":422,"type":20},"2026-12",{"name":39,"class":40},""]